Company Devyser Diagnostics AB

Equities

DVYSR

SE0016588867

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Devyser Diagnostics AB

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 06:35:54 2024-05-08 am EDT			5-day change	1st Jan Change
99 ^SEK	+5.77%		+0.20%	+25.95%

May. 08	Transcript : Devyser Diagnostics AB, Q1 2024 Earnings Call, May 08, 2024
May. 08	Devyser Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Devyser Diagnostics AB is a Sweden-based company engaged in development, manufacture ad sale of kits for genetic testing in routing diagnostic to laboratories. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The company has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnosticsâ products are sold directly to the end customer or through hired distributors. The Company provides its products in more than 45 countries.

Number of employees: 118

SEK in Million	2022	Weight	2023	Weight	Delta
Hereditary Diseases 65.0 %	-	-	110	65.0 %	-
Oncology 20.0 %	-	-	34	20.0 %	-
Transplantation 15.0 %	-	-	25	15.0 %	-

SEK in Million	2022	Weight	2023	Weight	Delta
Europe (excluding Sweden), Middle East and Africa 82.3 %	109	85.7 %	139	82.3 %	+28.42%
North and South America 8.2 %	3	2.5 %	14	8.2 %	+333.96%
Sweden 5.9 %	11	8.4 %	10	5.9 %	-6.06%
Asia 3.6 %	4	3.4 %	6	3.6 %	+43.77%

Managers	Title	Age	Since
Ulf Axel Klangby FOU	Founder	55	03-12-31
Fredrik Alpsten CEO	Chief Executive Officer	58	-
Sabina Berlin DFI	Director of Finance/CFO	41	20-12-31
Göran Rydin COO	Chief Operating Officer	55	20-12-31
Camilla Wiberg HRO	Human Resources Officer	-	22-08-31
Theis Kipling PRN	Corporate Officer/Principal	-	22-05-31

Members of the board	Title	Age	Since
Pia Magnhild Helena Gideon BRD	Director/Board Member	70	20-12-31
Hans Fredrik Mattsson BRD	Director/Board Member	52	21-12-31
Ingrid Mia Arnhult CHM	Chairman	55	09-12-31
Lars Höckenström BRD	Director/Board Member	68	15-12-31
Ulf Axel Klangby FOU	Founder	55	03-12-31
Fredrik Dahl BRD	Director/Board Member	-	20-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	16,284,469	8,370,589 ( 51.40 %)	0	51.40 %

Name	Equities	%	Valuation
Hans Jarl Rutger Arnhult 24.24 %	3,912,916	24.24 %	37 M kr
Swedbank Robur Fonder AB 8.080 %	1,304,100	8.080 %	12 M kr
Fjärde AP-fonden 6.839 %	1,103,821	6.839 %	10 M kr
Ferd AS (Private Equity) 6.196 %	1,000,000	6.196 %	9 M kr
Joh. Berenberg, Gossler & Co. KG (Investment Management) 6.196 %	1,000,000	6.196 %	9 M kr
Anders Hedrum 4.932 %	796,020	4.932 %	8 M kr
Ulf Axel Klangby 4.463 %	720,300	4.463 %	7 M kr
Dan Hauzenberger 3.393 %	547,680	3.393 %	5 M kr
Lupus alpha Asset Management AG 1.239 %	200,000	1.239 %	2 M kr
Fredrik Alpsten 1.207 %	194,879	1.207 %	2 M kr

Devyser Diagnostics AB

Instrumentvägen 19

126 53, Hägersten

+46 8 56 21 58 50

http://www.devyser.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

63.01 DKK

Average target price

80.73 DKK

Spread / Average Target

+28.12%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
DEVYSER DIAGNOSTICS AB	+25.95%	148M
MODERNA, INC.	+22.56%	46.71B
LONZA GROUP AG	+48.83%	41.8B
IQVIA HOLDINGS INC.	-1.51%	41.52B
CELLTRION, INC.	-3.42%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.13%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.44%	19.26B
BIO-TECHNE CORPORATION	-0.14%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.47%	12.08B
MEDPACE HOLDINGS, INC.	+26.45%	11.98B

Other Biotechnology & Medical Research